Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study

OBJECTIVES: Regarding reactogenicity and immunogenicity, heterologous COVID-19 vaccination regimens are considered as an alternative to conventional immunization schemes. METHODS: Individuals receiving either heterologous (ChAdOx1-S [AstraZeneca, Cambridge, UK]/BNT162b2 [Pfizer-BioNTech, Mainz, Germ...

Descripción completa

Detalles Bibliográficos
Autores principales: Kohmer, Niko, Stein, Shivana, Schenk, Barbara, Grikscheit, Katharina, Metzler, Melinda, Rabenau, Holger F., Widera, Marek, Herrmann, Eva, Wicker, Sabine, Ciesek, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800011/
https://www.ncbi.nlm.nih.gov/pubmed/36587839
http://dx.doi.org/10.1016/j.ijid.2022.12.034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800011/
https://www.ncbi.nlm.nih.gov/pubmed/36587839
http://dx.doi.org/10.1016/j.ijid.2022.12.034

Ejemplares similares